All that Jazz: Why this Palo Alto drug maker is growing

Favicon The San Francisco Business Times

Jazz Pharmaceuticals plc is feeling the rhythm of growth. Fresh off winning Food and Drug Administration approval of a leukemia-fighting drug, the Ireland-domiciled, Palo Alto-based drug developer (NASDAQ: JAZZ) soon will move into a new, 98,000-square-foot office building in Stanford Research Park, which it agreed to lease in early 2015 for $66 per square foot. Last month, it said it would pay more than $74 a square foot for a 100,000-square-foot structure on the site of its current home just down...

Read the full article here: The San Francisco Business Times


The post: «All that Jazz: Why this Palo Alto drug maker is growing» has been published on the website The San Francisco Business Times where, everyday, you can find the latest news about San Francisco's area.



Get more articles about this topic

Leave a comment